- Home
- WSC vs RARE Comparison
WSC vs RARE Comparison
Compare WSC & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WSC | RARE |
|---|---|---|
| Founded | 1944 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Corporate Leasing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.2B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | WSC | RARE |
|---|---|---|
| Price | $20.03 | $36.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 15 |
| Target Price | $25.43 | ★ $85.20 |
| AVG Volume (30 Days) | ★ 4.0M | 1.4M |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | ★ 1.37% | N/A |
| EPS Growth | ★ 816.06 | N/A |
| EPS | ★ 1.20 | N/A |
| Revenue | ★ $2,317,990,000.00 | $630,598,000.00 |
| Revenue This Year | N/A | $19.09 |
| Revenue Next Year | N/A | $20.62 |
| P/E Ratio | $17.00 | ★ N/A |
| Revenue Growth | N/A | ★ 20.63 |
| 52 Week Low | $14.91 | $25.81 |
| 52 Week High | $39.61 | $49.19 |
Technical Indicators
Market Signals| Indicator | WSC | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 50.51 | 62.29 |
| Support Level | $20.08 | $35.65 |
| Resistance Level | $21.45 | $36.74 |
| Average True Range (ATR) | 0.96 | 1.38 |
| MACD | 0.20 | 0.15 |
| Stochastic Oscillator | 55.38 | 55.94 |
Price Performance
Historical ComparisonAbout WSC WillScot Mobile Mini Holdings Corp.
WillScot Holdings Corp designs, delivers, and services onsite, on-demand space solutions for clients. The company offers turnkey solutions in construction, education, manufacturing, retail, healthcare, and entertainment sectors. The products of the company includes modular office complexes, mobile offices, portable storage containers, and others.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.